1. ALK gene rearrangement is an important biological characteristic of non-small cell lung cancer.
2. The ALK gene rearrangement positive non-small cell lung cancer zoledronic treatment rate in patients is effective up to 95%.
3. Non-small cell lung cancer patients must undergo ALK gene rearrangement before treatment with zoledronic drugs.
4. ALK gene rearrangement test has successfully become a routine molecular program for the lung cancer pathology precise therapy.